Published in
American College of Physicians, Annals of Internal Medicine, 10(160), p. 672
DOI: 10.7326/m13-2498
Links
- ORCID
- American College of Physicians
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [citeseerx.ist.psu.edu] | PDF
- [annals.org] | PDF
Tools
Cost-Effectiveness of the Children's Oncology Group Long-Term Follow-up Screening Guidelines for Childhood Cancer Survivors at Risk for Treatment-Related Heart Failure
Journal article published in 2014 by
F. Lennie Wong,
Smita Bhatia,
Wendy Landier,
Liton Francisco,
Wendy Leisenring 
,
Melissa M. Hudson,
Gregory T. Armstrong,
Ann Mertens,
Marilyn Stovall,
Leslie L. Robison,
Gary H. Lyman,
Steven E. Lipshultz,
Saro H. Armenian
,
Melissa M. Hudson,
Gregory T. Armstrong,
Ann Mertens,
Marilyn Stovall,
Leslie L. Robison,
Gary H. Lyman,
Steven E. Lipshultz,
Saro H. Armenian
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
Full text: Unavailable
Postprint:
archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Childhood cancer survivors treated with anthracyclines are at high risk for asymptomatic left ventricular dysfunction (ALVD), subsequent heart failure, and death. The consensus-based Children's Oncology Group (COG) Long-Term Follow-up Guidelines recommend lifetime echocardiographic screening for ALVD.